Tricuspid Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: 1-year Outcomes From the TRILUMINATE Randomized Cohort

JACC Associate Editor Celina M. Yong, MD, FACC, and JACC: Case Reports Editor in Chief Gilbert H. L. Tang, MD, MSc, MBA, FACC, discuss this paper published in JACC and presented at TCT. TRILUMINATE Pivotal is the first randomized, controlled trial evaluating transcatheter edge-to-edge repair (T-TEER) for severe tricuspid regurgitation (TR). Adaptive design randomized 572 subjects in the primary or subsequent cohorts. Subjects were elderly with atrial fibrillation and prior HFH. Primary endpoint was met at 1 year with a larger win ratio for T-TEER driven by KCCQ improvement with no significant differences in mortality and tricuspid valve surgery or HFH.

Om Podcasten

Each week, Valentin Fuster, MD, PhD, MACC, records free podcasts highlighting journal findings. To keep clinicians updated on the most important science emerging in clinical and translational cardiology, Dr. Fuster provides an overview of the weekly edition from the Journal of the American College of Cardiology (JACC), as well as a short summary of each manuscript. Encompassing JACC and nine cardiovascular specialty journals, the JACC family of journals rank among the top cardiovascular peer-reviewed journals in the world for scientific impact.